DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Talnetant
Talnetant
Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
Modifications to the Harmonized Tariff Schedule of the United States To
I Regulations
Neurokinin Receptor NK Receptor
Review Article
Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects Of
Stembook 2018.Pdf
Crystal Structure of the Human NK1 Tachykinin Receptor
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
Bidirectional Regulation of Human Colonic Smooth Muscle
Cover Page the Handle
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Tachykinin Receptors and Gastrointestinal Motility: Focus on Humans
Human Recombinant NK3 Tachykinin Receptor Stable Cell Line Cat. No
Neurokinin Receptor NK Receptor
Localization and Function of Nk3 Subtype Tachykinin
Customs Tariff - Schedule Xxi - 1
Top View
Characterization of Species-Related Differences in the Pharmacology Of
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
In Vitro and in Vivo Characterization of the Non-Peptide NK3 Receptor
Reference: WLI/100 28 March 2007
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Pathophysiological Concepts of Functional Dyspepsia and Irritable Bowel Syndrome Future Pharmacotherapy
Me-Talnetant and Osanetant Interact Within Overlapping but Not Identical